PMID- 32713874
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 84
IP  - 9
DP  - 2020 Aug 25
TI  - Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean 
      Patients With Acute Coronary Syndrome.
PG  - 1582-1586
LID - 10.1253/circj.CJ-20-0125 [doi]
AB  - BACKGROUND: Dual antiplatelet therapy is commonly used for patients with acute 
      coronary syndrome (ACS). This study aimed to evaluate the safety and efficacy of 
      aspirin and prasugrel at standard dosages in Korean patients using clinical 
      outcome data.Methods and Results:For this prospective multicenter phase IV 
      post-marketing surveillance (PMS) study, ACS patients from 29 July 2012 to 28 
      July 2016 were recruited. Patients received aspirin at a dose of 75-150 mg daily 
      and a standard dose of prasugrel. Bleeding events were recorded and summarized to 
      evaluate safety. Data on adverse events (AEs) and composite events such as 
      cardiovascular (CV) death, myocardial infarction (MI), and stroke were recorded 
      and summarized to assess efficacy. Of the 3,283 patients recruited, data from 
      3,110 and 3,044 patients were included in the safety and efficacy analyses, 
      respectively (median treatment duration, 172 days). The most frequently reported 
      AE was ecchymosis (2.8%). The number of patients with major bleeding was 29/3,110 
      (0.93%). The discontinuation rate for any reason was 12.6%. The number of cases 
      that ended in CV death, MI, stroke, stent thrombosis, or unplanned coronary 
      revascularization was 26/3,044 (0.85%). CONCLUSIONS: The present results are 
      similar to those observed in clinical trials where administration of low-dose 
      aspirin plus prasugrel was associated with a low rate of major bleeding and CV 
      events.
FAU - Chon, Min-Ku
AU  - Chon MK
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Jung, Soon-Myung
AU  - Jung SM
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Lee, Soo-Yong
AU  - Lee SY
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Lee, Sang-Hyun
AU  - Lee SH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Hwang, Ki-Won
AU  - Hwang KW
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Choi, Jin-Hee
AU  - Choi JH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Kim, Jeong-Su
AU  - Kim JS
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Park, Yong-Hyun
AU  - Park YH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Kim, June-Hong
AU  - Kim JH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
FAU - Chun, Kook-Jin
AU  - Chun KJ
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200722
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/epidemiology
MH  - Aged
MH  - Aspirin/*adverse effects
MH  - Coronary Thrombosis/*chemically induced/epidemiology
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents/*adverse effects
MH  - Female
MH  - Hemorrhage/*chemically induced/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*chemically induced/epidemiology
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Prasugrel Hydrochloride/*adverse effects
MH  - Prospective Studies
MH  - Republic of Korea/epidemiology
MH  - Stroke/*chemically induced/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Platelet aggregation inhibitors
OT  - Prasugrel hydrochloride
OT  - Prospective studies
OT  - Thrombosis
EDAT- 2020/07/28 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1253/circj.CJ-20-0125 [doi]
PST - ppublish
SO  - Circ J. 2020 Aug 25;84(9):1582-1586. doi: 10.1253/circj.CJ-20-0125. Epub 2020 Jul 
      22.